Mori 1989.

Methods	Randomisation: “assigned at random”. Blinding: double‐blind. Duration: 8 weeks. Design: parallel. Location: not indicated. Setting: “mainly inpatients” (inpatients and outpatients).
Participants	Diagnosis: schizophrenia. N = 167. Gender: 101M, 66F. Age: not indicated. History: duration stable: not indicated, duration of illness: "most of the participants have schizophrenia for more than 10 years", number of previous hospitalisations: not indicated, age at onset: not indicated, severity of illness: not indicated, baseline antipsychotic dose: not indicated.
Interventions	1. Haloperidol: fixed/flexible dose: not indicated, dose range: maximum dose 20 mg/day, mean dose: not indicated. N = 86. 2. Nemonapride: fixed/flexible dose: not indicated, dose range: maximum dose 30 mg/day, mean dose: not indicated. N = 81. Rescue medication: anti‐Parkinsonian, hypnotics, antipsychotics, antidepressant, and anti‐anxiety drugs were allowed.
Outcomes	Examined: Clinically important response to treatment: Global Improvement rating. Leaving the study early due to any reason. Adverse effects: akathisia, akinesia, dystonia, rigor, tardive dystonia, tremor, use of antiparkinson medication, sedation. Unable to use: Mental state general: Brief Psychiatric Rating Scale (BPRS) (no raw data available). Mental state specific: Scale for the Assessment of Negative Symptoms (SANS) (no raw data available).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	“Patients were assigned at random to either the YM‐09151 or the Haloperidol group”. No further details.
Allocation concealment (selection bias)	Unclear risk	No further details.
Blinding (performance bias and detection bias) (performance bias)	Low risk	“Double‐blind”. “Both drugs were confirmed as being indistinguishable from each other, having an identical appearance, and identical colour shades and weights, by two controllers.”
Blinding (performance bias and detection bias) (detection bias)	Unclear risk	“Double‐blind”. No further details.
Incomplete outcome data (attrition bias) All outcomes	Low risk	The number of participants randomised to each treatment group were 81 for YM‐09151 and 86 for Haloperidol. 27 participants left the study early, but the uncompleted data were also subjected to statistic analysis.
Selective reporting (reporting bias)	High risk	The outcome data were not fully addressed (no raw data for the BPRS and SANS).
Other bias	Unclear risk	Insufficient information to assess whether an important risk of bias exists.